References
Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I, Fujita Y, Okinaga S, Hirano H, Yoshimori K, Harada T, Ogura T, Ando M, Miyazawa H, Tanaka T, Saijo Y, Hagiwara K, Morita S, Nukiwa T (2010) Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362:2380–2388
Shaw AT, Kim DW, Nakagawa K, Seto T, Crino L, Ahn MJ, De Pas T, Besse B, Solomon BJ, Blackhall F, Wu YL, Thomas M, O’Byrne KJ, Moro-Sibilot D, Camidge DR, Mok T, Hirsh V, Riely GJ, Iyer S, Tassell V, Polli A, Wilner KD, Janne PA (2013) Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 368:2385–2394
Ahn HK, Jeon K, Yoo H, Han B, Lee SJ, Park H, Lee MJ, Ha SY, Han JH, Sun JM, Ahn JS, Ahn MJ, Park K (2013) Successful treatment with crizotinib in mechanically ventilated patients with ALK positive non-small-cell lung cancer. J Thorac Oncol 8:250–253
van Geffen WH, Hiltermann TJ, Groen HJ (2013) Surviving respiratory insufficiency with intensive care support in a pretreated, extensively metastasized patient with an EML4-ALK translocation. J Thorac Oncol 8:e1–e2
Toffart AC, Minet C, Raynard B, Schwebel C, Hamidfar-Roy R, Diab S, Quetant S, Moro-Sibilot D, Azoulay E, Timsit JF (2011) Use of intensive care in patients with nonresectable lung cancer. Chest 139:101–108
Conflict of interest
ACT: Roche, Boehringer Ingelheim; XD: Boehringer Ingelheim; CAV: Roche, AstraZenea, Boehringer Ingelheim, Pfizer; BM: Roche, AstraZenea, Boehringer Ingelheim, Pfizer; PF: Roche, AstraZenea, Boehringer Ingelheim, Pfizer; DMS: Roche, AstraZenea, Boehringer Ingelheim, Pfizer; NG, CC, MD, AP and JFT declared that they have no competing interests.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Toffart, AC., Dhalluin, X., Girard, N. et al. Patients with advanced lung cancer harboring oncogenic mutations should be admitted to intensive care units. Intensive Care Med 41, 164–165 (2015). https://doi.org/10.1007/s00134-014-3535-x
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00134-014-3535-x